REGULATORY

Chuikyo Payers Signal Mixed Views on Off-Year Drug Price Revisions

February 16, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Members representing the payer side of the Central Social Insurance Medical Council (Chuikyo) met the press on February 13 following the panel’s recommendation on the FY2026 medical fee revision, offering mixed signals on the future of off-year drug price revisions.…

To read the full story

Chuikyo Issues FY2026 Fee Revision Recommendation, Creates New Premiums for Generics and Biosimilars
February 16, 2026

REGULATORY

PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
LDP Returnees Set Sights on Social Security, Drug Policy as Special Diet Opens
February 18, 2026
10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
February 17, 2026
MHLW to Brand OTC-Like Drug Cost Rule as “Partially Non-Insured Care”
February 17, 2026
Taiyo Pharma’s Propranolol Designated as Drug for Specific Use
February 17, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…